NewsEvents

Your Yourlocation: Home > Study on the Evaluation of Tiotropium bromide(136310-93-5) in Foreign Countries

The utility indicators were generally obtained through the European Five-dimensional Health Scale (EQ-5D) questionnaire, or the St. George Respiratory (SGRQ) questionnaire. The objective of drug economics evaluation for COPD drugs was not only the comparison of single drugs, the comparison of the two regimens, and the comparison of the three regimens. According to the comparison of tiotropium bromide(136310-93-5) and routine care, UPLIFT experiment was used as the data source. By constructing the Markov decision model, the patients with COPD in Italy were treated with tiotropium in one year for one cycle. (QALY) as the utility index, it was found that 0.42 QALY was obtained in patients with COPD with tiotropium, and the incidence of deterioration was reduced. The pharmacokinetic evaluation of tiotropium bromide(136310-93-5) and salmeterol was usually based on the construction of the Markov model, and the duration of the study was based on a one-year study. In a relatively short period of time, the effects of the two drugs on COPD Condition improvement. At the same time, the QALY value of tiotropium was 0.70, the QALY value of salmeterol was 0.68, and the triclosan was the same as the drug price Higher than salmeterol, but its improvement in worsening conditions can reduce the cost of patients with acute hospitalization, resulting in more cost-effectiveness. In addition to tiotropium, tiotropium was compared with salmeterol, and the addition of ipratropium bromide was used to compare the three regimens. Ipratropium bromide is a short-acting LAMA, its efficacy duration is shorter, the number of daily administration more. There is also a study of the cost-effectiveness analysis and budget impact analysis of the three treatment regimens using tiotropium bromide(136310-93-5), ipratropium bromide and salmeterol in British COPD patients from the perspective of the British National Health Service System. The markov state is divided into mild, moderate and severe three states, while each state according to the deterioration of the situation is divided into serious deterioration and mild deterioration, to 1 month time for a markov cycle, run 1 year, and finally concluded that tiotropium is more cost-effective than salmeterol and ipratropium bromide.

Abroad for COPD drug economics evaluation carried out earlier, but also developed a more comprehensive and mature. Whether it is from the perspective of disease staging, different mechanisms of action of the drug point of view, or the use of different decision-making model point of view, the use of different years of study perspective, etc., can be related to the study.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved